JPH05500953A - 免疫共役体およびその代謝物の非標的保持量を減少させる方法 - Google Patents

免疫共役体およびその代謝物の非標的保持量を減少させる方法

Info

Publication number
JPH05500953A
JPH05500953A JP2514345A JP51434590A JPH05500953A JP H05500953 A JPH05500953 A JP H05500953A JP 2514345 A JP2514345 A JP 2514345A JP 51434590 A JP51434590 A JP 51434590A JP H05500953 A JPH05500953 A JP H05500953A
Authority
JP
Japan
Prior art keywords
target
moiety
immunoconjugate
metabolites
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2514345A
Other languages
English (en)
Japanese (ja)
Inventor
グレイ　マリー　アン
アクスワーシー　ドン
ウィルケニング　ディビッド
Original Assignee
ネオルクス　コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオルクス　コーポレイション filed Critical ネオルクス　コーポレイション
Publication of JPH05500953A publication Critical patent/JPH05500953A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2514345A 1989-09-29 1990-09-24 免疫共役体およびその代謝物の非標的保持量を減少させる方法 Pending JPH05500953A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41505589A 1989-09-29 1989-09-29
US415,055 1989-09-29

Publications (1)

Publication Number Publication Date
JPH05500953A true JPH05500953A (ja) 1993-02-25

Family

ID=23644186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2514345A Pending JPH05500953A (ja) 1989-09-29 1990-09-24 免疫共役体およびその代謝物の非標的保持量を減少させる方法

Country Status (7)

Country Link
US (2) US5380513A (enExample)
EP (1) EP0494247B1 (enExample)
JP (1) JPH05500953A (enExample)
AT (1) ATE136224T1 (enExample)
CA (1) CA2066031C (enExample)
DE (1) DE69026387T2 (enExample)
WO (1) WO1991004755A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504395A (ja) * 1999-07-16 2003-02-04 マリンクロッド・インコーポレイテッド 腎臓に有害な可能性のある分子の腎臓取り込みの阻害

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2066031C (en) * 1989-09-29 2001-02-27 Mary A. Gray Methods for reducing non-target retention of immunoconjugates and metabolites thereof
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
ITMI20010347A1 (it) * 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
EP1419786A1 (en) * 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
US20070184501A1 (en) * 2006-02-07 2007-08-09 Beckman Coulter, Inc. Blocker reagent for reduction of heterophile interferences
EP4674439A1 (en) * 2023-03-02 2026-01-07 Nihon Medi-Physics Co., Ltd. Radioactive metal labeled antibody, radiopharmaceutical, and compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916213A (en) * 1983-02-22 1990-04-10 Xoma Corporation Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
EP0268707A3 (en) * 1985-11-05 1989-03-08 The General Hospital Corporation Negatively charged specific affinity reagents
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy
CA1340312C (en) * 1986-10-09 1999-01-12 Paul G. Abrams Methods for improved targeting of antibody, antibody fragments, hormonesand other targeting agents and conjugates thereof
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4946675A (en) * 1987-05-27 1990-08-07 Xoma Corporation Hepatic blocking agents
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
CA2066031C (en) * 1989-09-29 2001-02-27 Mary A. Gray Methods for reducing non-target retention of immunoconjugates and metabolites thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504395A (ja) * 1999-07-16 2003-02-04 マリンクロッド・インコーポレイテッド 腎臓に有害な可能性のある分子の腎臓取り込みの阻害

Also Published As

Publication number Publication date
EP0494247B1 (en) 1996-04-03
US5380513A (en) 1995-01-10
CA2066031A1 (en) 1991-03-30
EP0494247A1 (en) 1992-07-15
CA2066031C (en) 2001-02-27
DE69026387T2 (de) 1996-11-28
DE69026387D1 (de) 1996-05-09
EP0494247A4 (enExample) 1994-03-30
WO1991004755A1 (en) 1991-04-18
ATE136224T1 (de) 1996-04-15
US5648059A (en) 1997-07-15

Similar Documents

Publication Publication Date Title
US5990286A (en) Antibodies with reduced net positive charge
EP0263046B1 (en) Affinity enhancement immunological reagents for detection and killing of specific target cells
AU649079B2 (en) Modified antibodies with controlled clearance time
US6203775B1 (en) Chelating polymers for labeling of proteins
EP0627939B1 (en) Conjugates of biotin and deferoxamine for radioimmunoimaging and radioimmunotherapy
JPH05502236A (ja) 感染性及び炎症性病変の検出及び治療のためのキメラ抗体
Smith-Jones et al. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA–MORAb-003
CN107735110A (zh) 纳米粒子免疫偶联物
JPH085808B2 (ja) 化合物標的化組成物
Vugts et al. Synthesis of phosphine and antibody–azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach
JPH03500419A (ja) 多特異抗白血球結合体及び哺乳動物用非経口的注射剤
JPH0651720B2 (ja) 抗体−キレート剤結合体
JPS6270377A (ja) ハプテンで修飾された診断薬および治療薬の抗体コンプレツクス
JPH0762032B2 (ja) 改良された放射性核種抗体カツプリング
ES2316961T3 (es) Conjugados para la formacion de imagenes medicas que comprenden portador, resto orientador y un agente de contraste.
JP2012131808A (ja) 減少した正味の正電荷を有する抗体
JPH10509425A (ja) 標的放射線療法のためのタンパク質の放射性リン標識
JP3074160B2 (ja) 悪性腫瘍用画像化剤
Yang et al. Formulation and preclinical testing of Tc-99m-labeled HYNIC-Glc-FAPT as a FAP-targeting tumor radiotracer
JPH05500953A (ja) 免疫共役体およびその代謝物の非標的保持量を減少させる方法
WO1997025069A9 (en) Antibodies with reduced net positive charge
JP2005047821A (ja) シクロペンタジエニルカルボニル基を含む放射性化合物を用いた診断及び治療用薬剤
CN121041473A (zh) 一种双功能性融合蛋白、放射性核素标记物及其应用
JPH05178826A (ja) 二官能性キレート化剤、それと蛋白質との複合体及びその用途
Perälä et al. Biodistribution in normal mice of an111in-labelled prostatic acid phosphatase-specific antibody and its F (ab′) 2 fragments derivatized site-specifically or via bicyclic diethyl enetriaminepentaacetic acid anhydride